We partner with healthcare and biotechnology companies to navigate critical moments by communicating the science, strategy, and value behind their innovation.
New York City
Joined November 2008
- Tweets13.4K
- Following1.4K
- Followers1.6K
- Likes9.2K
Pinned Tweet
The new Russo Partners website is live. Explore our Insights hub, the Russo Edge Podcast, and how we work across media, IR, digital, and strategy to translate complex science into clear stories. bit.ly/3WtK0Il
#Biotech #LifeSciences #Healthcare #PR
Russo Partners retweeted
#NEWS: Boehringer Ingelheim advances COPD pipeline with Phase III trial registration. Learn more: boehringer-ingelheim.com/us/…
Russo Partners retweeted
$LCTX’s @CEO_Culley is looking forward to joining Ben Beneski, SVP & CTO of @AllogeneTx, on the next live @_CellandGenewebinar, moderated by @Erin_Harris1 to discuss the requirements for #celltherapy late-stage development and commercialization.
Register to watch on 11/12 here: event.on24.com/wcc/r/5524667…
#CellTherapy #GeneTherapy #RegenerativeMedicine #ReplaceandRestore
Spinal cord injury drugs may need a different kind of clinical trial. In @Citeline’s In Vivo, Bridget Silverman speaks with former @FDA chief Janet Woodcock on why the condition calls for more flexible, patient-centered endpoints.
insights.citeline.com/in-viv…
#SpinalCordInjury #FDA
Revuforj has been named one of @TIME’s Best Inventions of 2026. The first FDA-approved oral menin inhibitor, born from 30+ years of research, helps abnormal blood cells develop more normally in people living with certain genetically driven acute leukemias. Read more here: time.com/collection/best-inv…
Russo Partners retweeted
Ossium CEO @KevinCaldweII on the @Nasdaq tower in Times Square, recognized as a 2026 @Biocom Catalyst Award winner.
Russo Partners retweeted
Congratulations to our CEO James Mackay, Ph.D., on receiving the President’s Convergence Award from @ljiresearch, honoring partnership at the intersection of science, medicine, and community. bit.ly/4zgtIFf
#Biotech #SanDiego
Russo Partners retweeted
$LCTX today provided an update on its ReSonanceTM (ANP1) program for #hearingloss. The program is built on our patented AlloSCOPETMmanufacturing platform, and is currently being developed under a research collaboration with William Demant Invest A/S (WDI).
Learn more: investor.lineagecell.com/new…
@CEO_Culley | #ReplaceAndRestore #CellTherapy #HearingLoss #RegenerativeMedicine @ca_navntoft
Russo Partners retweeted
Could immune education be targeted?
In a preclinical melanoma mouse model, FibroBiologics studied a thymus organoid designed to direct immune activity toward a specific target.
The research remains preclinical.
👉 See the full presentation: bit.ly/how-immunity-ages
$FBLG
#FibroBiologics #Immunology #CancerResearch
On the Russo Edge, @SolomonsWisdom sits down with Harris Kaplan of Litmys, author of Approval Is Not Adoption, to unpack why safe and effective isn’t always better.
▶️ Interview & video: bit.ly/4yI3vyg
🎙️ Apple Podcasts: apple.co/3WQKpJ5
#Biotech #DrugDevelopment
Russo Partners retweeted
#CTS2026 replays are now available on demand.
$LCTX’s @CEO_Culley was proud to sit alongside presenters from @AbbVie, Oculis, @Valitorbio, @NeurotechPharma, @RecenseM and others, as part of the “From Innovation to Approval: Bringing Novel Treatments to Market” panel, moderated by Pravin U. Dugel, M.D., of @OCUTX.
Watch the recorded sessions: ctsretina.org/
#CTSRetina #ClinicalTrials #Ophthalmology #CellTherapy #ReplaceandRestore | @CEO_Culley @ArshadKhanani @CTS_Tahoe
Russo Partners retweeted
In a new @ClinicalLeader1 interview, our CEO @KevinCaldweII explains why Ossium took a multi-center approach from its earliest study.
To date, 29 patients have been treated with Ossium’s organ donor-derived bone marrow at roughly half as many centers, each using the conditioning regimens and post-transplant care its team already knew. The goal was to generate data that reflects real-world transplant practice.
We're now carrying that approach into PRESERVE II, a 300-patient, three-arm study that begins enrollment in 2027.
Read the full interview: clinicalleader.com/doc/ossiu…
Russo Partners retweeted
What if the future of diabetes treatment depends on WHERE a medicine acts - not just which medicine we use?
On this episode of @ProgressPotent1 I'm joined by Robert Geho, Co-Founder and CEO of @Diasome Pharmaceuticals
For decades, insulin therapy has helped millions of people manage diabetes. But conventional injected insulin reaches the general circulation before the liver -the organ that plays a central role in regulating glucose metabolism.
Diasome is developing a different approach.
Its proprietary Hepatocyte-Directed Vesicle (HDV) technology is designed to direct insulin toward liver cells, with the goal of improving glucose regulation while reducing hypoglycemia.
In our conversation, we explore:
🧬 Why the liver is so important to normal insulin physiology;
🔬 How HDV technology is designed to change insulin delivery;
📊 What Diasome's Phase 2b OPTI-2 results tell us;
💉 Whether liver-targeted insulin could complement today's insulin therapies;
⚖️ Why the company is also investigating HDV-based approaches to GLP-1 and serotonin signaling;
And we'll tackle a bigger question: Could more precise drug delivery open new possibilities for treating metabolic disease?
The science is fascinating. The clinical evidence compelling. And the next steps will determine whether this approach can make a meaningful difference for patients.
Watch now - youtube.com/watch?v=jx6ZfxpO…
#Diabetes #Biotechnology #DrugDelivery #MetabolicHealth #MedicalInnovation @russopartners
🤖 Made with AI
Russo Partners retweeted
🎉 2 weeks until Impact Night!
There's still time to join NYC's life science community on Nov 4 at Time Out Market, Union Square for a night that turns connection into change.
🎟️ Individual $500 | Party of 3 $1,350
👉host.nxt.blackbaud.com/regis…
#ImpactNight #NYC #LifeSciences
Russo Partners retweeted
We're proud to be named @GenomeWeb's 2026 Best Places to Work—for the second year in a row!
This recognition is especially meaningful because it comes directly from our employees. It reflects the collaboration, shared purpose and supportive culture that bring our mission to life everyday.
To our entire Lucid Diagnostics team, thank you for the dedication, passion and commitment you bring to our work and to one another. We're proud of what we've built together and excited for what's ahead.
#BestPlacesToWork #Team
Russo Partners retweeted
Nice to see our partner highlighting RPE cell therapy. At #AAO2026, #retina specialists heard firsthand about treatments that can make a meaningful difference for #dryAMD patients.
$LCTX #OpRegen #ReplaceandRestore @CEO_Culley
Russo Partners retweeted
Thrilled to announce that Revuforj® (revumenib) was named one of @TIME's Best Inventions of 2026!
We’re honored to be recognized for advancing the next generation of innovative therapies for patients who need them most. Today and always, we thank the Syndaxers, clinicians, investigators and patients who have played a pivotal role in shaping the future of medicine.
Learn more:
ir.syndax.com/news-releases/…
#TIMEBestInventions
Russo Partners retweeted
Are there some things you don't know about Lambert-Eaton myasthenic syndrome (LEMS)? LEMS is considered a rare disease, and since some of its symptoms are similar to other diseases, it is frequently misdiagnosed.
Learn more: catalystpharma.com/lems
#LEMS #raredisease
Russo Partners retweeted
$LCTX congratulates @ca_navntoft and the Eriksholm Research Center for their review of the current status of cell therapy for restoring auditory nerve function, which highlights the importance of combining #celltherapy with surgical approaches to help people with hearing loss.
We look forward to continued progress on our ReSonance® (ANP1) program, an auditory neuronal cell transplant program to treat hearing loss.
Read the full article: sciencedirect.com/science/ar…
#ReplaceAndRestore #HearingLoss | @CEO_Culley
Russo Partners retweeted
Coya today announced plans to initiate an open-label extension (OLE) of the Phase 2/3 ALSTARS Trial evaluating COYA 302 for the treatment of amyotrophic lateral sclerosis (#ALS).
We plan to initiate the OLE in response to requests from ALSTARS investigators and study participants. “The strong interest from investigators and participants in continuing treatment beyond the current 48-week study period underscores the importance of providing continued access to COYA 302 for eligible participants in the ALSTARS trial,” said Dr. Fred Grossman, DO, FAPA, our President and Chief Medical Officer.
For more details: businesswire.com/news/home/2…
#EndALS
